Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to explore efficacy and safety of neoadjuvant nivolumab for
non-metastatic upper tract urothelial carcinoma (UTUC), and explore the potential predictive
biomarkers of immunotherapy.